期刊文献+

桉叶提取物抑制黄嘌呤氧化酶活性成分的分离纯化及其动力学研究 被引量:6

Inhibition effects on xanthine oxidase and kinetics research of extracts from eucalyptus leaves
下载PDF
导出
摘要 为了对尾巨桉属广林9号品种桉叶提取物进行体外抑制黄嘌呤氧化酶(XOD)活性研究,并对其主要活性成分进行分离纯化、结构鉴定及抑制动力学研究。采用高效液相色谱法(HPLC)检测酶反应生成尿酸的量,以甲醇-K2HPO4缓冲液(50 mmol/L,pH值7.5)(5∶95)为流动相,检测波长为290 nm,测定了桉叶的不同溶剂提取物及其萃取组分对XOD活性的抑制作用,确定了最佳提取条件,并采用Diaion HP-20大孔树脂、反相硅胶柱层析法和制备液相色谱仪进行分离纯化。确定桉叶中最高活性单体为鞣花酸、槲皮素-3-O-葡萄糖苷酸和五没食子酰葡萄糖,测得其IC50分别为22.51、32.96、31.75μg/mL;并通过酶抑制动力学试验比较了他们的抑制类型和Ki值,得出鞣花酸的Ki值最小、为1.048μg/mL,可知其抑制黄嘌呤氧化酶活性效果在3种活性单体中最优。 Purified the anti-hyperuricemic components from Guanglin No.9 eucalyptus leaves by screening xanthine oxidase inhibitory activity in vitro and identified their structures. The inhibitory effects of extracts from eucalyptus leaves on xanthine oxidase (XOD) were measured by HPLC analysis. The mobile phases consisted of methanol-K2HPO4 buffer liquid (50mmol/L, pH 7.5, 5:95) and detection wavelength was 290 nm. The inhibitory effects on XOD of different extracts from eucalyptus leaves were determined to confirm the optimal extraction conditions, and used Diaion HP-20 macroporous resin, ODS and preparation HPLC to purify the extracts from eucalyptus leaves. The most active compounds, which were ellagic acid, Quercetin-3-O-glucuronide and Pentagalloyl glucose, were isolated with ICes 22.51, 32.96, 31.75 μg/mL, respectively. The inhibitory types and Kis of these three compounds were also studied through kinetics research, as the Ki of ellagic acid was minimum, 1.048 μg/mL, so the inhibitory effect on XOD of the ellagic acid was the best among these three compounds.
出处 《广东农业科学》 CAS CSCD 北大核心 2014年第14期100-105,共6页 Guangdong Agricultural Sciences
基金 国家林业公益性行业科研专项(201104003-03)
关键词 桉叶提取物 黄嘌呤氧化酶 高效液相色谱法 分离纯化 结构鉴定 eucalyptus leaves xanthine oxidase high performance liquid chromatography purification structure characterization
  • 相关文献

参考文献19

  • 1刘爱军,邢丽岩.2型糖尿病合并高尿酸血症的临床观察[J].实用临床医药杂志,2007,11(5):118-118. 被引量:14
  • 2Puig J G, Martfnez M A. Hyperuricemia, gout and the metabolic syndrome[J].Curr Opin Rheumatol,2008, 20(2):187-91.
  • 3Grobner W, Waiter S I.T reatment of hyperuricemia and gout [J].MedMonatsschrPharm,2005,28(5):159-164.
  • 4陈光亮,王琳琳,徐叔云.防治痛风的药物研究进展[J].国外医学(内分泌学分册),2005,25(4):277-279. 被引量:15
  • 5Bomalaski J S, Clark M A. Serum uric acid-lowering therapies: where are we leading in management of hyperuricemia and the potential role of uricase[J].Curr Rheumatol Rep,2004,6(3):240- 247.
  • 6肖苏尧,陈雪香,陈运娇,王俊亮,汤杰,曹庸.桉叶抗氧化作用研究进展[J].食品工业科技,2012,33(14):396-399. 被引量:12
  • 7何耀松,张继东.桉树化学成分及药理作用研究进展[J].动物医学进展,2007,28(7):98-101. 被引量:25
  • 8付文卫,赵春杰,裴玉萍,王瑞杰,窦德强,陈英杰.桉属植物的化学成分与生物活性[J].国外医药(植物药分册),2003,18(2):51-58. 被引量:23
  • 9Vazquez G, Gonzalez-Alvarez J, Santos J, et al.Evaluation of potential applications for chestnut (Castanea sativa) shell and Eucalyptus (Eucalyptus globulus) bark extracts [J].Industrial Crops and Products,2009,29 (2-3):364-370.
  • 10Kulkarni A, Suzuki S, Etoh H. Antioxidant compounds from Eucalyptus grandis biomass by subcritical liquid water extraction [J].Journal of Wood Science,2008,54(2):153-157.

二级参考文献173

共引文献118

同被引文献106

引证文献6

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部